JP2005517025A5 - - Google Patents

Download PDF

Info

Publication number
JP2005517025A5
JP2005517025A5 JP2003566523A JP2003566523A JP2005517025A5 JP 2005517025 A5 JP2005517025 A5 JP 2005517025A5 JP 2003566523 A JP2003566523 A JP 2003566523A JP 2003566523 A JP2003566523 A JP 2003566523A JP 2005517025 A5 JP2005517025 A5 JP 2005517025A5
Authority
JP
Japan
Prior art keywords
cell
reagents
cell population
polyclonality
shift
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003566523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/005850 external-priority patent/WO2003067221A2/en
Publication of JP2005517025A publication Critical patent/JP2005517025A/ja
Publication of JP2005517025A5 publication Critical patent/JP2005517025A5/ja
Ceased legal-status Critical Current

Links

JP2003566523A 2002-02-08 2003-02-07 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 Ceased JP2005517025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35539102P 2002-02-08 2002-02-08
US37573302P 2002-04-26 2002-04-26
PCT/US2003/005850 WO2003067221A2 (en) 2002-02-08 2003-02-07 Compositions and methods for restoring immune responsiveness in patients with immunological defects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010226115A Division JP2011036264A (ja) 2002-02-08 2010-10-06 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法

Publications (2)

Publication Number Publication Date
JP2005517025A JP2005517025A (ja) 2005-06-09
JP2005517025A5 true JP2005517025A5 (cg-RX-API-DMAC7.html) 2006-03-23

Family

ID=27737495

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003566523A Ceased JP2005517025A (ja) 2002-02-08 2003-02-07 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
JP2010226115A Pending JP2011036264A (ja) 2002-02-08 2010-10-06 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010226115A Pending JP2011036264A (ja) 2002-02-08 2010-10-06 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法

Country Status (7)

Country Link
US (3) US20040005298A1 (cg-RX-API-DMAC7.html)
EP (2) EP1472341A4 (cg-RX-API-DMAC7.html)
JP (2) JP2005517025A (cg-RX-API-DMAC7.html)
AU (2) AU2003216436A1 (cg-RX-API-DMAC7.html)
CA (1) CA2474186A1 (cg-RX-API-DMAC7.html)
TW (1) TW200307129A (cg-RX-API-DMAC7.html)
WO (1) WO2003067221A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
US20060286089A1 (en) * 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2008016431A2 (en) * 2006-07-29 2008-02-07 Robert Lamar Bjork Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
WO2010099205A1 (en) 2009-02-24 2010-09-02 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (pml)
CA2791975C (en) 2010-02-04 2021-02-09 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
EP2518504A1 (en) * 2011-04-29 2012-10-31 Miltenyi Biotec GmbH A method for the quantitative and qualitative characterization of antigen-specific T cells recognizing a specific antigen
BR102013020194A2 (pt) * 2012-08-31 2014-10-29 Gm Global Tech Operations Inc Estrutura de posicionamento e reforço para um veículo, conjunto da extremidade dianteira para um veículo, e, veículo
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
AU2014302771A1 (en) * 2013-06-24 2016-01-28 Celgene Corporation Methods of expanding T cells
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
WO2015148512A1 (en) 2014-03-24 2015-10-01 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
EP3091032A1 (en) * 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
US9790467B2 (en) 2015-09-22 2017-10-17 Qt Holdings Corp Methods and compositions for activation or expansion of T lymphocytes
AU2017305948B2 (en) 2016-08-01 2023-12-14 Academia Sinica Internally fixed lipid vesicle
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58117537A (ja) * 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
US5081029A (en) * 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
US6071517A (en) 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5837447A (en) * 1992-04-15 1998-11-17 Blood Center Research Foundation, Inc., The Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69433970T2 (de) 1993-08-10 2005-08-11 W.L. Gore & Associates, Inc., Newark Zelleinkapselungsvorrichtung
JPH09510201A (ja) 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド 臨床的効用を有する二重特異性分子
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JPH10503964A (ja) 1995-06-07 1998-04-14 ゴア ハイブリッド テクノロジーズ,インコーポレイティド 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
DE69739951D1 (de) * 1996-03-04 2010-09-16 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
CA2278847A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US6867041B2 (en) * 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) * 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
AU779289B2 (en) * 2000-05-25 2005-01-13 Xcyte Therapies, Inc. Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation

Similar Documents

Publication Publication Date Title
DE69503903D1 (de) Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung
JP2006502416A5 (cg-RX-API-DMAC7.html)
DE69230146D1 (de) Monoklonale antikörper gegen putative hcv-e2/ns1-proteine und verfahren zu ihrer verwendung
JP2007510622A5 (cg-RX-API-DMAC7.html)
JP2002513156A5 (cg-RX-API-DMAC7.html)
JP2003527832A5 (cg-RX-API-DMAC7.html)
JP5753775B2 (ja) 化学合成した核酸の純度を測定する方法と組成物
JP2012107019A5 (cg-RX-API-DMAC7.html)
JP2008503720A5 (cg-RX-API-DMAC7.html)
CA2406240A1 (en) Hcv anti-core monoclonal antibodies
JP2009518039A5 (cg-RX-API-DMAC7.html)
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
JP2008518884A5 (cg-RX-API-DMAC7.html)
JP2002518460A5 (cg-RX-API-DMAC7.html)
JP2016505634A5 (cg-RX-API-DMAC7.html)
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2004528574A5 (cg-RX-API-DMAC7.html)
WO2005092926A3 (en) Reducing the risk of human and anti-human antibodies through v gene manipulation
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
JP2004532839A5 (cg-RX-API-DMAC7.html)
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
JP2007526908A5 (cg-RX-API-DMAC7.html)
JP2019531716A5 (cg-RX-API-DMAC7.html)
CY1110144T1 (el) Αντισωματα για την ταυτοποιηση και/ή την απομονωση τουλαχιστον ενος κυτταρικου πληθυσμου ο οποιος επιλεγεται απο την ομαδα την περιλαμβανουσα αιμοποιητικα βλαστοκυτταρα, νευρικα βλαστοκυτταρα, νευρικα αρχεγονα κυτταρα, μεσεγχυματικα βλαστοκυτταρα και μεσεγχυματικα αρχεγονα κυτταρα